The study tested the effects of balcinrenone/dapagliflozin, a drug combination, both in fed and fasted states, and with the addition of quinidine, a P-gp inhibitor. The purpose is to understand how ...

Dapagliflozin delivers cardiometabolic benefits in patients with myocardial infarction, regardless of their baseline A1c ...

A new study published in the European Journal of Medical Research revealed that dapagliflozin, a sodium-glucose ...

Dapagliflozin is a novel, selective, sodium glucose co-transporter 2 (SGLT2) inhibitor, currently being evaluated in Phase 3 trials as a once-daily oral therapy for the treatment of type 2 diabetes.

Dapagliflozin, an investigational compound, is a potential first-in-class sodium-glucose cotransporter-2 (SGLT2) inhibitor currently in Phase 3 trials under joint development by Bristol-Myers ...

Dapagliflozin significantly reduced the risk of all-cause mortality or worsening heart failure by 28% in high-risk patients undergoing transcatheter aortic valve implantation (TAVI).

Kato E, et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus based on ejection fraction [published online March 18, 2019]. Circulation. Verma S, McMurray JJV.

Dapagliflozin may exert a protective effect on kidney function in patients with chronic kidney disease associated with autosomal dominant polycystic kidney disease (ADPKD) when used in conjunction ...

The Dapagliflozin in Respiratory Failure in Patients With COVID-19 trial is the first phase 3 study to examine whether this SGLT2 inhibitor, which has proven effective for multiple chronic ...

Dapagliflozin was well tolerated among patients with an eGFR of less than 60 mL/minute per 1.73² and among those with an eGFR of greater than or equal to 60 mL/minute per 1.73².

Dapagliflozin was well tolerated and the rate of treatment discontinuation was low in patients with and without diabetes. Hypoglycemia and diabetic ketoacidosis developed only in patients with ...

The study tested the effects of balcinrenone/dapagliflozin, a combination drug, in different conditions: fasted, fed, and with the P-gp inhibitor quinidine. The goal was to understand how these ...